These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Stein GE; Wells EM Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. Hau T Eur J Clin Microbiol Infect Dis; 2002 Jul; 21(7):491-8. PubMed ID: 12172739 [TBL] [Abstract][Full Text] [Related]
9. Linezolid for the treatment of resistant gram-positive cocci. Bain KT; Wittbrodt ET Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064 [TBL] [Abstract][Full Text] [Related]
10. Use of linezolid in children: an overview of recent advances. Velissariou IM Expert Rev Anti Infect Ther; 2006 Dec; 4(6):947-52. PubMed ID: 17181410 [TBL] [Abstract][Full Text] [Related]
11. Linezolid in children: recent patents and advances. Velissariou IM Recent Pat Antiinfect Drug Discov; 2007 Jan; 2(1):73-7. PubMed ID: 18221164 [TBL] [Abstract][Full Text] [Related]
12. Linezolid - the first oxazolidinone in the treatment of nosocomial MRSA pneumonia. Burkhardt O; Pletz MW; Mertgen CP; Welte T Recent Pat Antiinfect Drug Discov; 2007 Jun; 2(2):123-30. PubMed ID: 18221168 [TBL] [Abstract][Full Text] [Related]
13. [Comparison of linezolid and vancomycin in nosocomial pneumonia: results of the multicenter double-blind study]. Grudinina SA; Zubkov MM; Krotova LA; Kurdiukova IuP; Kutsenko MA; Marinin VF; Sidorenko SV; Sinpal'nikov AI; Solomatin AS; Sterkhova GV; Fesenko OV; Fomina IG; Chuchalin AG Antibiot Khimioter; 2002; 47(1):12-7. PubMed ID: 12077934 [TBL] [Abstract][Full Text] [Related]
14. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections. Falagas ME; Vardakas KZ Drug Saf; 2008; 31(9):753-68. PubMed ID: 18707190 [TBL] [Abstract][Full Text] [Related]
15. Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic. Corti G; Cinelli R; Paradisi F Int J Antimicrob Agents; 2000 Dec; 16(4):527-30. PubMed ID: 11118873 [TBL] [Abstract][Full Text] [Related]
17. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy. Pletz MW; Burkhardt O; Welte T Eur J Med Res; 2010 Nov; 15(12):507-13. PubMed ID: 21163725 [TBL] [Abstract][Full Text] [Related]
18. Linezolid: a review of its use in the management of serious gram-positive infections. Perry CM; Jarvis B Drugs; 2001; 61(4):525-51. PubMed ID: 11324682 [TBL] [Abstract][Full Text] [Related]
19. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Wang Y; Zou Y; Xie J; Wang T; Zheng X; He H; Dong W; Xing J; Dong Y Eur J Clin Pharmacol; 2015 Jan; 71(1):107-15. PubMed ID: 25355172 [TBL] [Abstract][Full Text] [Related]
20. Two new treatment options for infections due to drug-resistant gram-positive cocci. Rehm SJ Cleve Clin J Med; 2002 May; 69(5):397-401, 405-13. PubMed ID: 12022383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]